{"3963": " when not all exacerbation events occurred during the viral infection", "3855": " viral infection increases airway inflammation which aggravates disease symptoms", "3856": " Recent advances in in vitro air-liquid interface 3D cultures, organoid cultures and the use of novel human and animal challenge models", "3854": " Respiratory virus infection", "3857": " recent novel findings that elucidate how respiratory viral infections alter the epithelial barrier in the airways", "3858": "What have the authors reviewed?ays, the upper airway microbial environment, epigenetic modifications including miRNA modulation, and other changes in immune responses throughout the upper and lower airways. First, we reviewed the prevalence of different respiratory viral infections", "3859": "", "3860": "", "3861": " the understanding of viral induced exacerbation in chronic airway inflammatory diseases", "3862": " airway inflammation", "3863": " both the upper airway (such as chronic rhinosinusitis, CRS) and lower airway", "3864": " complexity and heterogeneity of the disease", "3865": " episodic exacerbations of the disease", "3866": " the effect of enhanced acute airway inflammation", "3867": " morbidity and sometimes mortality in patients", "3869": " the presence of environmental factors", "3870": " infiltration of activated immune cells", "3871": "", "3872": " high", "3873": " ease of transmission and infection", "3874": " exacerbations of different nature and severity", "3875": " to properly manage exacerbations via supplementary treatments that may alleviate the exacerbation symptoms or prevent severe exacerbations", "3876": " dysregulated inflammation", "3877": "", "3878": " recent findings of viral interaction with the upper airway", "3879": "", "3880": " bacterial infections", "3881": "", "3882": " Rhinovirus (RV) and respiratory syncytial virus (RSV)", "3883": " parainfluenza virus (PIV), influenza virus (IFV) and adenovirus (AdV)", "3884": " bocavirus (BoV), human metapneumovirus (HMPV), certain coronavirus (CoV) strains, a specific enterovirus (EV) strain EV-D68, human cytomegalovirus (hCMV) and herpes simplex virus (HSV)", "3885": " they can infect both the upper and/or lower airway", "3886": " airway epithelial cells", "3887": " the cells release antiviral factors and cytokines that alter local airway inflammation and airway niche", "3888": " type 1 inflammatory responses", "3891": "", "3892": " compiling and collating the current known mechanisms of viral-induced exacerbation of chronic airway inflammatory diseases", "3893": " to provide further understanding of viral induced exacerbation", "3894": " the current scarcity of antiviral drugs for the management of viral-induced exacerbations", "3941": " viruses evoke an inflammatory response", "3942": " release type I (IFN\u03b1/\u03b2) and type III (IFN\u03bb) interferons, cytokines and chemokines", "3943": "", "3944": " worsens the symptoms of airway diseases", "3945": " viral infections such as RV and RSV promote a Type 2-biased immune response (Becker, 2006; Jackson et al., 2014; Jurak et al., 2018) . This amplifies the basal type 2 inflammation resulting in a greater release of IL-4, IL-5, IL-13, RANTES and eotaxin and a further increase in eosinophilia", "3946": " worsens the classical symptoms of disease and may further lead to life-threatening conditions due to breathing difficulties", "3947": "", "3948": " IL-25, IL-33 and TSLP", "3949": " ILC2s", "3950": " induce the expression of IL-25, IL-33 and TSLP", "3951": "What happens when the 3 cytokines are expressed?ldsmith et al., 2012; Byers et al., 2013; Shaw et al., 2013; Beale et al., 2014; Jackson et al., 2014; Uller and Persson, 2018; Ravanetti et al., 2019) . These 3 cytokines then work in concert to activate ILC2s to further secrete type 2 cytokines IL-4, IL-5, and IL-13 which further aggravate the type 2 inflammation in the airway causing acute exacerbation", "3952": " increased ILC2 activation", "3954": "What happens during viral infection of healthy individuals?d further aggravate the exacerbation (Silver et al., 2016) . Interestingly, these factors are not released to any great extent and do not activate an ILC2 response", "3960": " antiviral state will be activated to clear the invading pathogen from the airway", "3961": " strengthening the neutrophilic infiltration in COPD airway, and eosinophilic infiltration in the asthmatic airway", "3962": " viral infection", "3964": " the nasal epithelium remains the primary site of most infections", "3965": " a more complex interplay between the virus and upper airway epithelium", "3966": " viral infections or their components persist in patients with chronic airway inflammatory disease (Kling et al., 2005; Wood et al., 2011; Ravi et al., 2019) . Hence, their presence may further alter the local environment and contribute to current and future exacerbations", "3967": "", "3968": " to determine the contribution of the microbiome and mycobiome to viral infections", "3969": " recent data regarding viral interactions with the airway epithelium", "3970": "Patients with chronic airway inflammatory diseases", "3971": " type 2-skewed inflammatory response", "3972": " weak type 1 inflammation-inducing viruses", "3973": " reduced type I (IFN\u03b2) and III (IFN\u03bb) interferon production", "3974": " prolong airway inflammation", "3975": " enhance granulocyte infiltration thus prolonging the exacerbation symptoms", "3976": " human papilloma virus", "3977": "", "3978": " steroid resistance", "3979": " cause the virus to linger longer in the airway", "3980": " acute exacerbation", "3981": " IFV (Yan et al., 2016; Guibas et al., 2018) and certain CoV", "3982": " massive damage and cell death to the epithelial barrier", "3983": " compounds the cell deaths", "3984": " further contact with other pathogens and allergens in the airway", "3985": " further epithelial remodeling", "3986": " annual influenza vaccination", "3987": " induction of vasodilation or tight junction opening factors", "3988": " disruption of tight junctions", "3989": " IFV infection was found to induce oncostatin M (OSM) which causes tight junction opening", "3990": " the expression of vasodilating factors and fluid homeostatic factors", "3991": "", "3992": " specific bacterial species in the microbiome", "3993": " destabilize the equilibrium of the microbiome present", "3994": " nutrient profile in the airway", "3995": " impaired bacterial immune response", "3996": " more far reaching effect", "3997": " the interplay between virus and pathogenic bacteria in exacerbating chronic airway inflammatory diseases", "3998": "How effective are microbiome based  trial therapies? pathogenic bacteria in exacerbating chronic airway inflammatory diseases (Wark et al., 2013; Singanayagam et al., 2018) . To counteract these effects, microbiome-based therapies are in their infancy but have shown efficacy in the treatments of irritable bowel syndrome by restoring the intestinal microbiome", "3999": " disruption of mucociliary function", "4000": " upper airway epithelium", "4001": " increase contact between environmental triggers with the lower airway and resident immune cells", "4002": " oxidative stress", "4003": " modulation of miRNAs and epigenetic modification", "4004": " growth of pathogenic bacteria", "4005": " inflammation and alteration of the lower airway environment", "4006": " RV, RSV, and IFV", "4007": " directly destroy the cilia of the ciliated cells", "4008": "", "4009": "", "4010": " short non-coding RNAs involved in post-transcriptional modulation of biological processes", "4011": " viral infections", "4012": " circulating miRNA changes", "4013": " the infected epithelium and responding immune cells", "4014": " increase miR-21 and augmented inflammation in experimental murine asthma models", "4015": " increase miR-125a and b, and miR-132 in COPD epithelium which inhibits A20 and MAVS", "4016": " miR-22 was shown to be suppressed in asthmatic epithelium in IFV infection which lead to aberrant epithelial response", "4017": " targets to modulate viral induced airway changes", "4018": " epigenetic modification", "4019": " the association of epigenetic modification and chronic airway inflammatory diseases", "4020": "", "4021": " antiviral factors such as IFN\u03b3 epigenetically modifies the viral resistance of epithelial cells", "4022": " an altered inflammatory state", "4023": " enhanced production of reactive oxygen species (ROS), oxidative stress and mitochondrial dysfunction in the airway epithelium", "4024": " constant oxidative stress", "4025": " trigger the further production of ROS as an antiviral mechanism", "4026": " infiltrating cells", "4027": " alter the management of the disease or confer resistance toward treatments that worked before", "4028": " important information regarding viral pathogenesis and changes induced within the airway of chronic airway inflammatory disease patients", "4029": " epithelial cell models", "4030": "For what  purpose animal based models aare developed for?o airway epithelial model that has been adapted to studying viral infection and the changes it induced in the airway (Yan et al., 2016; Boda et al., 2018; Tan et al., 2018a) . Animal-based diseased models have also been developed to identify systemic mechanisms of acute exacerbation", "4031": " the humanized mouse model", "4032": " verification of the associations of the virus with the proposed mechanism of viral induced acute exacerbations", "3868": " complex interactions between the host and the exacerbation agents", "3687": " long non-coding RNAs", "3688": " to calculate the relatedness of objects with the same or different types in a uniform framework", "3689": " protein-protein interaction", "3690": " regulates cell cycle and survival", "941": "", "933": "", "934": " fever, malaise, and vomiting", "935": " 35%", "936": " 10%", "937": "What vaccine can be used to prevent Venezuelan equine encephalitis virus?es a low infectious dose, and contains multiple serotypes. Both the former Soviet Union and the United States previously weaponized the virus, producing large quantities for their now defunct offensive bioweapons programs (4) . Currently, vaccine strain TC83", "938": " changes in gene expression", "939": " endoplasmic reticulum (ER) stress", "940": " inositolrequiring enzyme 1 (IRE1), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6) (33, 34)", "942": " nucleus", "943": " a transcription factor", "557": " 2012", "558": "", "559": " males more than females", "560": " Dromedary camels", "562": "", "563": "", "564": " no specific treatment", "565": " 40 and above", "279": " pyrin domain-containing 3 (NLRP3)", "280": " lipopolysaccharide-primed macrophages", "281": "What ion channel is essential for 3a-mediated IL-1Beta secretion?nflammasome remains unknown. Here, we provide direct evidence that SARS-CoV 3a protein activates the NLRP3 inflammasome in lipopolysaccharide-primed macrophages. SARS-CoV 3a was sufficient to cause the NLRP3 inflammasome activation. The ion channel activity of the 3a protein", "282": " transmembrane pore-forming viral proteins", "283": " Betacoronavirus", "284": " Coronaviridae", "285": " is an enveloped virus", "287": " single-stranded", "288": " 8,098", "289": " 9.6%,", "290": " tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2, and IL-6", "292": "How does NLRP3 detect RNA viral infection?h catalyzes the proteolytic processing of pro-IL-1\u03b2 and pro-IL-18 into their active forms and stimulates their secretion (Kayagaki et al., 2015; Shi et al., 2015) .\n\nIt is increasingly evident that NLRP3 detects RNA viruses by sensing the cellular damage or distress induced by viroporins", "293": " 76", "294": " Ca 2+ -permeable", "296": " NLRP3 inflammasome", "257": " 7.3 billion", "248": " Middle East respiratory syndrome coronavirus", "249": "Transmissibility and severity", "250": " January 30, 2020", "251": "H7N9", "252": "", "253": " 20% to 30%", "254": " 20%", "255": "", "1657": " 35\u202f000 to 60\u202f000", "1635": "", "3258": " Nuclear receptors (NRs)", "3259": " a class of ligand-inducible transcription factors", "3260": " homeostasis, differentiation, embryonic development, and organ physiology", "3261": " seven", "3262": " a reliable 3D (three dimensional) structure of the target protein", "3263": " X-ray crystallography", "3264": " time-consuming and expensive", "3265": " membrane proteins", "3266": " KEGG", "546": " hemorrhagic fever", "547": " enveloped, negative-sense RNA virus", "548": " rodents", "549": "", "551": " antiviral medicine", "552": " IFITM3 single nucleotide polymorphisms (SNP) rs12252 C allele and CC genotype", "554": " IFITM1, 2, 3, 5, and 10, among which IFITM1, 2, and 3", "555": " restrict viral infection at the stage of cellular entry", "556": " rs12252 C allele", "2754": " Bats-Hosts-Reservoir-People transmission network model", "2755": "What is the model simplified to?to the human infection", "2756": " 2.30 from reservoir to person and 3.58 from person to person", "2757": " Our model showed that the transmissibility of SARS-CoV-2 was higher than the Middle East respiratory syndrome in the Middle East countries, similar to severe acute respiratory syndrome, but lower than MERS in the Republic of Korea", "2758": "", "2759": " the virus transmitted among the bats, and then transmitted to unknown hosts (probably some wild animals). The hosts were hunted and sent to the seafood market which was defined as the reservoir of the virus. People exposed to the market got the risks of the infection (Fig. 1) . The BHRP transmission network model was based on the following assumptions or facts", "2760": " susceptible bats (S B ), exposed bats (E B ), infected bats (I B ), and removed bats (R B ).", "2761": " four", "2762": "", "2763": " five compartments", "2764": " 5.2 days", "2765": " 5-day", "2766": " 3 to 7 days", "2767": " 5.8 days", "2768": " 0.5 times that of symptomatic infection", "2769": " 0.3 million", "2770": " 2.87 million", "2771": " 2.7-3.4 or 2-4", "2772": "", "2773": " 0.8-1.3", "2774": "", "2775": " decrease R 0 .", "2776": " transmissibility of SARS-CoV-2 might be higher than MERS in the Middle East countries", "2777": " to provide a mathematical model for calculating the transmissibility of SARS-CoV-2", "5149": " through mucosal exposure to aerosols or by direct contact of abraded skin with infectious material", "5150": " Old World (OW) and New World (NW)", "5151": " OW Lassa virus", "5152": " live attenuated", "5153": " lung epithelial cells are one of the initial cell targets of humans following inhalation of mammarenavirions", "5154": "", "5155": " ouabain", "5156": "", "5157": "\nCombination therapy", "5158": "", "5159": " using genetics and pharmacological inhibition of the genes", "5175": "", "5176": " 8-30%", "5177": " alveolar macrophages", "5178": " The subsequent infection with Gram-positive bacteria", "5179": " Reduced TNF\u03b1 production by NK cells", "5180": " a pneumococcal pore-forming toxin", "5181": " epithelial barrier damage, exaggerated innate immune response, and cytokine storm", "568": " interferon-induced transmembrane", "569": " three", "570": " 2-bromopalmitic acid", "571": " IFITM5 with FKBP11", "572": " S-palmitoylation on IFITM5 promotes the interaction with FKBP11", "573": " S-palmitoylation on the protein", "574": " bonerestricted IFITM-like (BRIL) protein", "575": " the region upstream of the ifitm5 gene lacks the interferon regulatory elements", "576": " 65%", "577": "", "580": "", "5256": " 11 June 2009", "5257": " \u22651/40", "5258": " conferring 50% protection against a viral challenge", "5259": " a substantial proportion of Reunion Island's population had pre-existing immunity to 2009 pandemic influenza virus", "5260": " the residual signature of the remote exposure of these individuals to H1N1 viruses circulating before 1957", "5261": " 9 weeks", "3267": " 11,399", "3268": "49.2%)", "3269": "", "3270": " 2005", "3271": " cough, rhinitis, fever", "3272": "\u226414 years old", "3273": " 1.82:1", "4077": " to comprehensively investigate the viral epidemiology of adult RTIs", "4078": " 15", "4079": " 4.1% of cases", "4080": " parainfluenza infection, old age, and immunosuppression", "4081": " multilocus polymerase chain reaction coupled with electrospray ionization mass spectrometry (PCR/ESI-MS)", "4082": " if the patients met one of the following conditions: corticosteroid treatment, solid organ or hematopoietic stem cell recipient, or chemotherapy for an underlying malignancy during the past 6 months", "4083": " 9-month", "4084": " 263", "4085": "", "917": "", "918": " single-stranded, linear, and nonsegmented RNA", "919": "", "920": "20kb nucleotides", "921": " 5=", "502": "", "504": " New conjugate vaccines", "507": " approximately 900,000", "510": "How has the childhood population grown in the last two  decades?advances in pneumonia epidemiology, etiology, radiologic presentation and outcome in children.\n\nThe overall burden of childhood pneumonia has been reduced substantially over the last decade, despite an increase in the global childhood population from 605 million in 2000 to 664 million in 2015", "511": " 25%", "512": "", "513": "", "514": "", "515": "", "516": " significant morbidity and chronic disease", "517": "", "518": "Chest radiologic changes", "520": "Widespread use of pneumococcal conjugate vaccination and Haemophilus influenzae type B conjugate vaccination", "521": " 18%", "522": "", "524": "", "530": "", "532": "How have the incidence Empyema been reduced? period (2005 to 2010) [26] . In Scotland, incidence of empyema in children rose from 6.5 per million between 1981 and 1998, to 66 per million in 2005 [27] . These trends have been reversed since the introduction of pneumococcal conjugate vaccination-13", "533": "", "534": "", "535": "Why has pertussis immunity in infants has decreased in infants?nother etiology is pertussis. In the last decade there has also been a resurgence in pertussis cases, especially in highincome countries [44] . Because pertussis immunity after acellular pertussis vaccination is less long-lasting than immunity after wild-type infection or whole-cell vaccination, many women of child-bearing age have waning pertussis antibody levels. Their infants might therefore be born with low transplacental anti-pertussis immunoglobulin G levels", "536": "What is the effect of childhood tuberculosis in childhood pneumonia?ess have commonly reported M. tuberculosis [48, 49] . A recent systematic review of tuberculosis as a comorbidity of childhood pneumonia reported culture-confirmed disease in about 8% of cases [50] . Because intrathoracic tuberculosis disease is only culture-confirmed in a minority of cases, the true burden could be even higher; tuberculosis could therefore be an important contributor to childhood pneumonia incidence and mortality", "537": "", "538": " increases odds of pneumonia by 1.6 times", "539": " HIV infection", "540": "", "541": " Influenza vaccination during pregnancy is safe", "923": " a rare complication of pneumonia", "4573": " a dense or fluffy opacity that occupies a portion or whole of a lobe, or the entire lung", "5163": " point mutations", "5164": " a positive-sense single stranded RNA enveloped virus causing chronic hepatitis", "5165": " about 3,000 aminoacids", "5166": "p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B", "5167": " high mutation rate", "5168": "", "5169": " antigenic differences of their nucleoprotein and matrix protein", "5170": " influenza A", "2477": " severe joint pain", "2471": " fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia", "2470": " a mosquito-borne emerging pathogen", "2472": " Currently, there is no vaccine or antiviral treatment", "2473": " we summarize the evidence supporting these concepts", "2474": " a mosquito-borne pathogen", "2475": " an arthropod-borne virus", "2476": " Aedes aegypti", "2478": " Kimakonde", "2479": "that which contorts or bends up", "2480": "the illness of the bended walker", "2481": " in a sylvatic cycle", "2482": " Ae. aegypti and Ae. albopictus", "2483": " in an urban cycle", "2484": "The 2005-2006 epidemic of CHIKV", "2485": " over 46,000", "2486": " the epidemiology and global expansion of CHIKV", "2487": "", "2488": " three", "2489": " gene sequences of an Envelope protein", "2490": " between 50 and 310 y ago", "2491": "", "2492": " come a long way", "2493": "", "2494": "", "2495": "", "2496": "", "2497": "", "2498": " decreased dexterity, loss of mobility, and delayed reaction", "2499": " 40%", "2500": "", "2501": " muscles, joints, and skin connective tissues", "2502": "", "2503": "More than 50%", "2504": "What percentage die?ective tissues. The high number of nociceptive nerve endings found within the joints and muscle connective tissues can explain pain associated with CHIKF [25, 26] .\n\nMore than 50% of patients who suffer from severe CHIKF are over 65 y old, and more than 33%", "2505": " children", "2506": " respiratory failure, cardiovascular decompensation, meningoencephalitis, severe acute hepatitis, severe cutaneous effects, other central nervous system problems, and kidney failure", "2507": "", "2508": " CHIKV", "2509": " ecological pressure", "2510": " CHIKV's secondary vector species, Ae. albopictus, to supplement Ae. aegypti as its primary vector", "2511": "", "2512": " 34%", "2513": " Madagascar", "2514": "", "2515": " an increase in infectivity of Ae. albopictus", "2516": "", "2517": " 100 times more infective to Ae. albopictus than it was to Ae. aegypti", "2518": "", "2519": " over 300 y", "2520": "", "2521": "", "2522": " congenital illness and fetal death", "2523": " it is associated with a high degree of morbidity", "2524": " motherto-child transmission most likely happens transplacentally shortly before delivery", "2525": " nineteen cases of neonatal infection", "2526": "", "2527": "", "2528": " Category C pathogen", "2529": " its ability to induce cross-reactive immune responses against the three distinct phylogenetic groups of CHIKV", "4221": "", "328": "", "329": "", "330": " NK cells", "331": " Excessive reactive oxygen species", "332": " ROS"}